朗欧医药LONGER品牌怎么样 申请店铺

我要投票 朗欧医药LONGER在医疗器械行业中的票数:333 更新时间:2025-06-30
朗欧医药LONGER是哪个国家的品牌?「朗欧医药LONGER」是 深圳朗欧医药集团有限公司 旗下著名品牌。该品牌发源于广东省深圳市,由创始人邹翔在2004-07-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗欧医药LONGER品牌出海!将品牌入驻外推网,定制朗欧医药LONGER品牌推广信息,可以显著提高朗欧医药LONGER产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

朗欧医药LONGER怎么样

朗欧医药集团成立于2000年6月,是一家集医药研发、生产、销售的集团公司。集团拥有江苏朗欧药业有限公司(江苏徐州)、烟台中洲制药有限公司(山东烟台)、广西玉兰制药有限公司(广西梧州)、江苏圣朗药业有限公司(江苏南京)等GMP工业以及深圳朗欧及武汉朗帛GSP商业,拥有员工1500余人。

朗欧集团拥有丰富的产品线。产品覆盖抗生素类、消化类、神经类、精神类、麻醉类、呼吸类、心血管类等治疗领域,拥有221个药品批文。其中,广西玉兰制药有限公司产品定位:清热解毒专家,拥有痔疮片、功劳去火片、利尔眠片、桑椹颗粒等品种;烟台中洲制药有限公司产品定位:妇儿健康的守护者,拥有金莲花分散片、血宁片、心安宁片、叶酸片等品种。拥有复方双花颗粒、胃肠宁片、胃肠宁颗粒、格列吡嗪胶囊、复方氨酚葡锌片等核心产品;江苏朗欧药业有限公司产品定位:精麻药经典品牌,拥有氯硝西泮注射液、艾司唑仑注射液、氟哌啶醇注射液、氯普噻吨注射液、多塞平注射液等一批精麻药品。

朗欧集团拥有强大的生产能力。公司拥有片剂、胶囊剂、颗粒剂、糖浆剂、茶剂、注射剂等多条生产线。其中,广西玉兰制药有限公司年产片剂22亿片、颗粒剂1500吨、糖浆剂60万升、茶剂1300吨;烟台中洲制药有限公司年产片剂10亿片、胶囊剂2亿粒;江苏圣朗药业有限公司年产片剂10亿片、胶囊5亿粒、颗粒5千万袋、中药提取1000吨;江苏朗欧药业有限公司(原徐州莱恩药业有限公司)年产小容量注射剂可达10亿支。

朗欧集团拥有健全的营销网络。在全国建有10大事业部(国药事业部、心血管事业部、儿药事业部、精麻药事业部、呼吸事业部、抗感染事业部、坤药事业部、药械事业部、基低药事业部、品牌事业部)、30个省总大办事处,近千名销售精英。营销触角深入地县,产品进入全国10000多家医院及第2、第3终端。

朗欧集团拥有深厚的企业文化。多年的发展朗欧孕育和沉淀了具有自身特色的企业文化,倡导“团队精神、以人为本、孝敬父母、社会责任”的核心价值观;打造“感恩文化、欣赏文化、反省文化、宝宝文化、PK文化、勤俭文化及快乐文化”的企业文化;树立“做百年朗欧,做百强朗欧”的企业愿景;坚守“助力民族制药,守护国人健康”的企业使命。

朗欧集团拥有创新的发展理念。从产品创新到学术创新,从渠道创新到模式创新,朗欧集团的发展,一直就在创新的路上......聚焦资源,合力营销,联盟商业,创造多赢,这是朗欧在新医药形势下的再次创新之举。创新的朗欧,开放的朗欧,诚信的朗欧,共享的朗欧,愿与您一道搭建工商联盟的战略合作平台,同舟共济,携手奋进。


Founded in June 2000, longou Pharmaceutical Group is a group company integrating pharmaceutical research and development, production and sales. The group has GMP industries such as Jiangsu longou Pharmaceutical Co., Ltd. (Xuzhou, Jiangsu), Yantai Zhongzhou Pharmaceutical Co., Ltd. (Yantai, Shandong), Guangxi Yulan Pharmaceutical Co., Ltd. (Wuzhou, Guangxi), Jiangsu Shenglang Pharmaceutical Co., Ltd. (Nanjing, Jiangsu), and GSP businesses of Shenzhen longou and Wuhan Longbo, with more than 1500 employees. Longou group has a rich product line. The products cover antibiotic, digestive, neurological, mental, anesthetic, respiratory, cardiovascular and other treatment fields, with 221 drug approvals. Among them, the product positioning of Guangxi Yulan Pharmaceutical Co., Ltd.: a heat clearing and detoxifying expert, with hemorrhoids tablets, Gonglaoquhuo tablets, lilmian tablets, mulberry granules and other varieties; Yantai Zhongzhou Pharmaceutical Co., Ltd. Product Positioning: the guardian of women and children's health, with Jinlianhua dispersible tablets, Xuening tablets, Xinanning tablets, folic acid tablets and other varieties. The company has core products such as compound Shuanghua granules, Weichangning tablets, Weichangning granules, glipizide capsules, compound paracetamol and zinc gluconate tablets, etc.; the product positioning of Jiangsu longou Pharmaceutical Co., Ltd.: classic brand of fine anesthetics, with a batch of fine anesthetics such as clonazepam injection, estazolam injection, haloperidol injection, chloroprothiazide injection, doxepin injection, etc. Longou group has a strong production capacity. The company has tablet, capsule, granule, syrup, tea, injection and other production lines. Among them, Guangxi Yulan Pharmaceutical Co., Ltd. has an annual output of 2.2 billion tablets, 1500 tons of granules, 600000 liters of syrup and 1300 tons of tea; Yantai Zhongzhou Pharmaceutical Co., Ltd. has an annual output of 1 billion tablets and 200 million capsules; Jiangsu Shenglang Pharmaceutical Co., Ltd. has an annual output of 1 billion tablets, 500 million capsules, 50 million bags of granules and 1000 tons of traditional Chinese medicine extraction; Jiangsu longou Pharmaceutical Co., Ltd. (formerly Xuzhou Laien) Pharmaceutical Co., Ltd.) has an annual output of 1 billion small volume injections. Longou group has a sound marketing network. There are 10 business departments (national drug business department, cardiovascular business department, pediatrics business department, fine and anesthetics business department, respiratory business department, anti infection business department, Kun drug business department, pharmaceutical machinery business department, basic and low drug business department, brand business department), 30 provincial general offices and nearly 1000 sales elites. The products have entered more than 10000 hospitals and the second and third terminals. Longou group has a profound corporate culture. With years of development, longou has nurtured and precipitated its own corporate culture with its own characteristics, advocating the core values of "team spirit, people-oriented, filial piety to parents, and social responsibility"; building a corporate culture of "gratitude culture, appreciation culture, reflection culture, baby culture, PK culture, thrifty culture and happy culture"; establishing an enterprise of "being a longou for a century, being a top 100 longou" Vision: adhere to the corporate mission of "help national pharmaceutical, protect people's health". Longou group has innovative development concept. From product innovation to academic innovation, from channel innovation to model innovation, the development of longou group has always been on the way of innovation... Focusing on resources, joint marketing, alliance business, creating multi win, this is the second innovation of longou in the new pharmaceutical situation. The innovative, open, honest and shared longou are willing to work with you to build a strategic cooperation platform for business alliance, work together in the same boat and forge ahead hand in hand.

本文链接: https://brand.waitui.com/40e73e693.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

海康威视:加拿大市场在公司2024年营业收入占比中不足0.3%

36氪获悉,海康威视在互动平台表示,加拿大市场在海康威视2024年营业收入占比中不足0.3%,面对各种政治打压,海康威视会继续努力服务好全球客户,继续为加拿大的客户提供产品和服务,会继续坚定推进国际化,会继续提升全球产品竞争力。

2小时前

商业航天概念持续走高,博亚精工等多股涨停

36氪获悉,截至发稿,商业航天概念持续走高,博亚精工、凯美特气、利君股份、晨曦航空涨停,七丰精工、国科军工、爱乐达、星辰科技、豪能股份、中兵红箭等跟涨。

2小时前

美国关税冲击下,日本5月工业产出环比仅增0.5%,远逊于预期

周一公布的政府数据显示,日本5月工业产出增速低于预期,因美国全面加征关税威胁到日本本已脆弱的经济复苏。日本经济产业省的数据显示,5月份工业产出环比增长0.5%,远低于3.5%的市场预期中值。日本经济产业省调查的制造商预计,经季节调整后的6月份工业产出将增长0.3%,7月份将下降0.7%。美国关税的打击可能会破坏日本疲弱的经济复苏。(新浪财经)

2小时前

中信建投:下半年金价不排除会大幅回撤

36氪获悉,中信建投研报表示,1—4月金价大幅上涨至3500美元,核心是特朗普政策带来的不确定性。在下半年贸易缓和、复苏交易的判断下,黄金的短期利多不算明显,若叠加全球股市走强、俄乌冲突缓和等事件,风险偏好回升,在历史高位的金价不排除大幅回撤。

2小时前

股票型基金新发规模创近四年同期新高

2025年行至年中,截至6月27日,年内已发行成立661只基金(按基金成立日计算),合计发行份额为5261亿份,平均发行份额为7.96亿份,创历史新低。债券基金发行情况不佳,拖累基金整体发行成绩,与之相反的是股票型基金新发规模则创出近四年同期新高。细分类型中,股票型基金有380只,合计发行份额为1855.32亿份,占新发权益基金的近八成;其新发数量、规模同比分别增长66.67%和179.24%,发行规模达到2022年以来同期新高。这主要得益于指数型基金的贡献:上半年成立366只指数基金,总发行份额为1832.03亿份,占据股票型基金新发规模的绝大部分。(中国基金报)

2小时前

本页详细列出关于朗欧医药LONGER的品牌信息,含品牌所属公司介绍,朗欧医药LONGER所处行业的品牌地位及优势。
咨询